Target intelligence / Profile preview

HIV-1 Gag capsid-spacer peptide 1 (CA-SP1) cleavage site (CA-SP1 junction)

Target
CA-SP1 junction
Molecular classification
Enzyme substrate site, Retroviral polyprotein cleavage site, Protease substrate
01

Overview

The CA-SP1 junction in HIV-1 Gag is a critical protease substrate site regulating viral maturation. During HIV-1 assembly, the Gag polyprotein forms a lattice structure wherein the CA-SP1 junction is sequestered within a 6-helix bundle, making it the slowest and final proteolytic cleavage event needed for maturation. Cleavage at this site enables dramatic structural rearrangements, producing the mature, infectious capsid particle. Small-molecule maturation inhibitors (e.g., Bevirimat) function by binding directly across the CA-SP1 junction, stabilizing the bundle and blocking protease-mediated cleavage. Targeting this specific junction has emerged as an attractive therapeutic approach in HIV/AIDS drug development. This site is not a receptor, enzyme, or transporter per se, but is a substrate sequence/domain within the HIV-1 polyprotein recognized by the HIV-1 protease, with pivotal biological and therapeutic relevance.

Other names
CA-SP1 sitecapsid-SP1 boundaryGag CA-SP1 junctionCA/SP1 cleavage siteCA-SP1 processing site
02

Mechanism of action

Inhibition of proteolytic cleavage at the CA-SP1 site prevents conversion of the immature HIV-1 Gag lattice into the mature capsid, thereby blocking viral infectivity and replication. Small molecules (maturation inhibitors) bind to the CA-SP1 junction, stabilizing the 6-helix bundle and physically hindering protease access.

03

Biological functions

Viral maturationCapsid assembly and reorganizationRegulation of HIV infectivity
04

Disease associations

Infection (HIV/AIDS)Antiviral drug target
05

Safety considerations

Development of viral resistance mutations (e.g., SP1 T8I mutation confers drug resistance)Off-target effects of maturation inhibitors are possible but generally less established than those for protease inhibitors
06

Interacting drugs

Bevirimat (BVM)

3 more in the full profile.

07

Biomarkers

CA-SP1 cleavage efficiency (used in HIV maturation assays and drug response studies)Presence of mature/immature capsid proteins in viral particles

Beyond the preview

Go deeper on HIV-1 Gag capsid-spacer peptide 1 (CA-SP1) cleavage site (CA-SP1 junction).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HIV-1 Gag capsid-spacer peptide 1 (CA-SP1) cleavage site (CA-SP1 junction).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call